Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986189

Next Previous
Drug Profile

BMS 986189

Alternative Names: BMS-986189; BMS-986189-07

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; PeptiDream
  • Class Anti-infectives; Antineoplastics; Peptides
  • Mechanism of Action Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Sepsis

Most Recent Events

  • 06 Aug 2025 BMS 986189 is still in preclinical trials for Cancer in Japan
  • 07 Dec 2022 Discontinued - Phase-I for Sepsis (In volunteers) in USA (unspecified route)
  • 06 Dec 2022 Preclinical trials in Cancer in Japan (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top